InvestorsHub Logo
Followers 4
Posts 381
Boards Moderated 0
Alias Born 10/20/2013

Re: couldbebetter post# 144510

Tuesday, 09/25/2018 7:12:33 AM

Tuesday, September 25, 2018 7:12:33 AM

Post# of 426316
couldbebetter: I'm right with you on this. Secondary endpoints are likely to be interesting and fruitful for us, when divulged. Dry eye syndrome has been anecdotally referenced, as has, Vascepa's anti-inflammatory action. $50 may end up being low in the case of BO. I'm in no hurry to sell.

Patience and conviction has been rewarded for those of us who stayed long during some pretty nasty storms. I'm in no hurry to sell.

I have to admit to having a clinically significant case of schadenfreude as I imagine some of the mouthy Shorts getting margin calls or having to explain to their spouse why they have to sell their house.

Karma is a bitch.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News